Article
Oncology
Dou-Dou Li, Zhong-hua Tao, Bi-Yun Wang, Lei-Ping Wang, Jun Cao, Xi-Chun Hu, Jian Zhang
Summary: This study aimed to evaluate the safety and efficacy of adding apatinib to chemotherapy in patients with advanced TNBC with failed first/second-line treatment. The results showed that the addition of apatinib to vinorelbine significantly improved progression-free survival compared to vinorelbine monotherapy, with minimal toxicity. Further exploration of this combination therapy is warranted.
Article
Oncology
Eleni Skavatsou, Maria Semitekolou, Ioannis Morianos, Theodoros Karampelas, Nikolaos Lougiakis, Georgina Xanthou, Constantin Tamvakopoulos
Summary: The combination of metronomic chemotherapy with immunotherapy shows potential efficacy and tolerability in the treatment of non-small cell lung cancer, providing new options for patients with reduced toxicities.
Article
Oncology
Alain Vergnenegre, Isabelle Monnet, Charles Ricordel, Acya Bizieux, Hubert Curcio, Marie Bernardi, Romain Corre, Florian Guisier, Stephane Hominal, Gwenaelle Le Garff, Olivier Bylicki, Chrystele Locher, Margaux Geier, Christos Chouaid, Gilles Robinet
Summary: This study evaluated the safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination therapy for stage IV non-small-cell lung cancer (NSCLC). The results showed that this regimen did not achieve the predefined progression-free survival (PFS) threshold, but no new safety signals were reported.
Article
Oncology
Chien-Ting Liu, Meng-Che Hsieh, Yu-Li Su, Chaio-Ming Hung, Sung-Nan Pei, Chun-Kai Liao, Yu-Fen Tsa, Hsiu-Yun Liao, Wei-Ching Liu, Chong-Chi Chi, Shih-Chung Wu, Shih-Ho Wang, Ching-Ting Wei, Kun-Ming Rau
Summary: Metronomic vinorelbine (mVNR) has shown promising efficacy and safety as salvage therapy for patients with advanced breast cancer (ABC), with a high overall response rate and disease control rate. Different subtypes of patients exhibited variations in time to treatment failure and overall survival time. Side effects were minimal and manageable, making mVNR a potential treatment option for ABC, especially when combined with targeted therapy or hormonal therapy. Further research should focus on optimizing dosage, schedule, and combination regimens for mVNR in ABC treatment.
Article
Medicine, General & Internal
Loice A. Ombajo, Jeremy Penner, Joseph Nkuranga, Jared Mecha, Margaret Mburu, Collins Odhiambo, Florentius Ndinya, Rukia Aksam, Richard Njenga, Simon Wahome, Peter Muiruri, Sheila Eshiwani, Maureen Kimani, Catherine Ngugi, Anton Pozniak
Summary: This study aimed to evaluate the efficacy of switching to dolutegravir in HIV-infected patients with viral suppression who were on second-line therapy with a ritonavir-boosted protease inhibitor (PI) and had no genotype information. The results showed that switching to dolutegravir was noninferior to continuing treatment with a ritonavir-boosted PI at 48 weeks in terms of viral suppression. No resistance mutations to dolutegravir or the ritonavir-boosted PI were detected at the time of treatment failure. The incidence of grade 3 or 4 adverse events related to treatment was similar between the two groups.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Review
Oncology
Jon Zugazagoitia, Luis Paz-Ares
Summary: Extensive-stage small-cell lung cancer is a challenging disease to treat, and despite improvements in first-line therapy, resistance remains a significant issue. Recent progress in understanding the molecular biology of SCLC holds potential for molecularly informed therapeutic strategies for patients with SCLC.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Hongxiang Huang, Peiyuan Zhong, Xie Zhu, Silv Fu, Siling Li, Sujuan Peng, Yangyang Liu, Zhihui Lu, Li Chen
Summary: This study retrospectively compared the efficacy and safety of immunotherapy plus rh-endostatin and immunotherapy plus chemotherapy in advanced non-small cell lung cancer patients. The results showed that the combination of immunotherapy and endostatin had longer progression-free survival, fewer adverse events, higher objective response rate, disease control rate, and 1-year overall survival rate.
FRONTIERS IN ONCOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Tao Jiang, Pingyang Wang, Jie Zhang, Yanqiu Zhao, Jianying Zhou, Yun Fan, Yongqian Shu, Xiaoqing Liu, Helong Zhang, Jianxing He, Guanghui Gao, Xiaoqian Mu, Zhang Bao, Yanjun Xu, Renhua Guo, Hong Wang, Lin Deng, Ningqiang Ma, Yalei Zhang, Hui Feng, Sheng Yao, Jiarui Wu, Luonan Chen, Caicun Zhou, Shengxiang Ren
Summary: This study investigated the efficacy and predictive biomarkers of toripalimab plus chemotherapy in EGFR-mutant advanced NSCLC patients as second-line treatment. The combination therapy showed promising anti-tumor activity with acceptable safety profiles, and DSPP mutation might serve as a potential biomarker for this combination. Further phase-III trials are ongoing to compare toripalimab versus placebo in this setting.
SIGNAL TRANSDUCTION AND TARGETED THERAPY
(2021)
Article
Oncology
Alison J. Moskowitz, Gunjan Shah, Heiko Schoeder, Nivetha Ganesan, Esther Drill, Helen Hancock, Theresa Davey, Leslie Perez, Sunyoung Ryu, Samia Sohail, Alayna Santarosa, Natasha Galasso, Rachel Neuman, Brielle Liotta, William Blouin, Anita Kumar, Oscar Lahoud, Connie L. Batlevi, Paul Hamlin, David J. Straus, Ildefonso Rodriguez-Rivera, Colette Owens, Philip Caron, Andrew M. Intlekofer, Audrey Hamilton, Steven M. Horwitz, Lorenzo Falchi, Erel Joffe, William Johnson, Christina Lee, M. Lia Palomba, Ariela Noy, Matthew J. Matasar, Georgios Pongas, Gilles Salles, Santosha Vardhana, Beatriz Wills Sanin, Gottfried von Keudell, Joachim Yahalom, Ahmet Dogan, Andrew D. Zelenetz, Craig H. Moskowitz
Summary: The study demonstrated that pembrolizumab in combination with gemcitabine, vinorelbine, and liposomal doxorubicin is an effective and well-tolerated second-line treatment for relapsed or refractory classical Hodgkin lymphoma, successfully bridging patients to high-dose therapy and autologous hematopoietic cell transplantation.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Merel J. M. van Velzen, Marieke Pape, Willemieke P. M. Dijksterhuis, Marije Slingerland, Theo van Voorthuizen, Laurens Beerepoot, Geert-Jan Creemers, Sarah Derks, Nadia H. Mohammad, Rob H. A. Verhoeven, Hanneke W. M. van Laarhoven
Summary: This study shows a positive correlation between the effectiveness of first-line therapy and outcomes of second-line therapy in gastro-oesophageal cancer. Patients with longer duration of first-line treatment failure had better survival outcomes with second-line therapy.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Medicine, General & Internal
A. Turkova, E. White, H. A. Mujuru, A. R. Kekitiinwa, C. M. Kityo, A. Violari, A. Lugemwa, T. R. Cressey, P. Musoke, E. Variava, M. F. Cotton, M. Archary, T. Puthanakit, O. Behuhuma, R. Kobbe, S. B. Welch, M. Bwakura-Dangarembizi, P. Amuge, E. Kaudha, L. Barlow-Mosha, S. Makumbi, N. Ramsagar, C. Ngampiyaskul, G. Musoro, L. Atwine, A. Liberty, V Musiime, D. Bbuye, G. M. Ahimbisibwe, S. Chalermpantmetagul, S. Ali, T. Sarfati, B. Wynne, C. Shakeshaft, A. Colbers, N. Klein, S. Bernays, Y. Saidi, A. Coelho, T. Grossele, A. Compagnucci, C. Giaquinto, P. Rojo, DFord, D. M. Gibb
Summary: In this trial involving children and adolescents with HIV-1 infection who were starting first- or second-line treatment, dolutegravir-based ART was found to be superior to standard care.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Oncology
Qiao Liu, Xia Luo, Zhen Zhou, Liubao Peng, Lidan Yi, Xiaomin Wan, Chongqing Tan, Xiaohui Zeng
Summary: The use of a PD-L1 test to guide second-line nivolumab treatment was not cost-effective from the perspective of the Chinese healthcare system. Negotiation with the National Healthcare Security Administration for a price reduction of nivolumab was found to be the most effective action to improve its cost-effectiveness in China.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Slavomir Krajnak, Thomas Decker, Lukas Schollenberger, Christian Rose, Christian Ruckes, Tanja Fehm, Christoph Thomssen, Nadia Harbeck, Marcus Schmidt
Summary: The VinoMetro study evaluated metronomic oral vinorelbine in HR+/HER2- breast cancer patients as a first-line chemotherapy, showing limited benefit and occurrence of severe adverse events. The study was closed early due to these findings.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2021)
Article
Clinical Neurology
Rafael Wabl, Samuel W. Terman, Maria Kwok, Jordan Elm, James Chamberlain, Robert Silbergleit, Chloe E. Hill
Summary: The study found that there was no significant difference in stopping seizures between patients who received a home medication and those who received a nonhome medication. However, retrospective evaluation suggested a potential association between receiving a nonhome medication and seizure cessation.
Article
Oncology
Meifang Li, Cheng Lin, Jinghui Lin, Shijie Chen, Lihong Weng, Zhiyong He
Summary: This study investigates the effects of osimertinib plus metronomic oral vinorelbine on EGFR-mutant advanced NSCLC beyond limited progression on osimertinib treatment. The results show that this combination therapy can prolong the progression-free survival and improve the disease control rate of patients, indicating its clinical efficacy.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY
(2023)
Article
Oncology
Maria A. Papadaki, Afroditi Sotiriou, Christina Vasilopoulou, Maria Filika, Despoina Aggouraki, Panormitis G. Tsoulfas, Christina A. Apostolopoulou, Konstantinos Rounis, Dimitrios Mavroudis, Sofia Agelaki
Article
Biochemistry & Molecular Biology
Maria A. Papadaki, Ippokratis Messaritakis, Oraianthi Fiste, John Souglakos, Eleni Politaki, Athanasios Kotsakis, Vassilis Georgoulias, Dimitrios Mavroudis, Sofia Agelaki
Summary: Detection of circulating tumor cells (CTCs) using CellSearch and CEACAM5 mRNA assays provides valuable and complementary clinical information for chemo-naive advanced or metastatic NSCLC patients. High CTC detection rates and the presence of CEACAM5 mRNA+ CTCs are associated with disease progression and shorter progression-free survival (PFS) and overall survival (OS).
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
Marcus Skribek, Konstantinos Rounis, Dimitrios Makrakis, Sofia Agelaki, Dimitris Mavroudis, Luigi De Petris, Simon Ekman, Georgios Tsakonas
Article
Oncology
Hara Polioudaki, Anastasia Mala, Eleni Gkimprixi, Maria A. Papadaki, Amanda Chantziou, Maria Tzardi, Dimitris Mavroudis, Sofia Agelaki, Panayiotis A. Theodoropoulos
Review
Oncology
Georgios Drillis, Maria Goulielmaki, Demetrios A. Spandidos, Sofia Aggelaki, Vassilios Zoumpourlis
Summary: Recent research has shown the important roles of non-coding RNAs in human diseases, particularly in cancer, with long non-coding RNAs playing a key role in oncogenesis and microRNAs showing promise as cancer molecular biomarkers. Studying the roles of non-coding RNAs in cancer leads to new hypotheses in the biology of cancer cells.
Article
Oncology
Konstantinos Rounis, Marcus Skribek, Dimitrios Makrakis, Luigi De Petris, Sofia Agelaki, Simon Ekman, Georgios Tsakonas
Summary: The study identified parameters that may potentially influence the intracranial outcome of patients with advanced NSCLC and brain metastases receiving PD-1/PD-L1 monotherapy, suggesting that age, history of CNS radiotherapy, and primary brain metastatic disease could impact the IC disease control probability. There is a lack of biomarkers for predicting intracranial outcomes in NSCLC patients with BM treated with ICIs, highlighting the need for further research in this area.
Article
Biochemistry & Molecular Biology
Chara Papadaki, Konstantina Thomopoulou, Alexia Monastirioti, George Koronakis, Maria A. Papadaki, Konstantinos Rounis, Lambros Vamvakas, Christoforos Nikolaou, Dimitrios Mavroudis, Sofia Agelaki
Summary: MicroRNAs play a crucial role in immune response regulation and tumor immune escape. In this study, miR-155 was found to be expressed lower in patients with early stage breast cancer compared to healthy women, and miR-155 and miR-10b were even lower in patients who experienced relapse. Combination of miR-19a and miR-20a expression showed the highest performance in discriminating patients with early relapse, while miR-10b combined with lymph node status and grade had the highest accuracy in discriminating patients with late relapse. Relapse predicting models based on circulating miRNAs may provide valuable insights for personalized treatment strategies in early stage breast cancer.
Article
Multidisciplinary Sciences
Konstantinos Rounis, Dimitrios Makrakis, Chara Papadaki, Alexia Monastirioti, Lambros Vamvakas, Konstantinos Kalbakis, Krystallia Gourlia, Iordanis Xanthopoulos, Ioannis Tsamardinos, Dimitrios Mavroudis, Sofia Agelaki
Summary: In patients with non-oncogenic driven metastatic non-small cell lung cancer, prolonged use of antibiotics, bone metastases, liver metastases, and low body mass index are important factors affecting treatment outcomes.
Article
Cell Biology
Alexia Monastirioti, Chara Papadaki, Konstantinos Rounis, Despoina Kalapanida, Dimitrios Mavroudis, Sofia Agelaki
Summary: The study revealed that high expression of miR-202 in non-small cell lung cancer patients is associated with disease progression, shorter progression-free survival, and overall survival. In subgroup analysis, miR-202 and miR-26a expression had different impacts on overall survival in squamous and non-squamous subgroups. These findings suggest that circulating miRNAs may serve as potential biomarkers in NSCLC patients.
Article
Oncology
Konstantinos Rounis, Dimitrios Makrakis, Alexandros-Pantelis Tsigkas, Alexandra Georgiou, Nikolaos Galanakis, Chara Papadaki, Alexia Monastirioti, Lambros Vamvakas, Konstantinos Kalbakis, Nikolaos Vardakis, Meropi Kontogianni, Ioannis Gioulbasanis, Dimitrios Mavroudis, Sofia Agelaki
Summary: The study found that CCS is associated with reduced efficacy of PD-1/PD-L1 inhibitors in NSCLC patients and should be an additional stratification factor in future I-O clinical trials. Further research at a translational and molecular level is needed to elucidate the mechanisms of metabolic deregulation and suppression of antitumor immunity.
TRANSLATIONAL LUNG CANCER RESEARCH
(2021)
Article
Biochemistry & Molecular Biology
Konstantina Thomopoulou, Chara Papadaki, Alexia Monastirioti, George Koronakis, Anastasia Mala, Despoina Kalapanida, Dimitrios Mavroudis, Sofia Agelaki
Summary: This study evaluated the differential expression of circulating miRNAs involved in immune response regulation in breast cancer progression. A 4-miRNA panel composed of miR-19a, miR-20a, miR-126, and miR-155 could distinguish between early and metastatic breast cancer patients. Low expression of miR-10b, miR-155, and miR-126 were associated with poorer disease free survival and overall survival outcomes in breast cancer patients.
FRONTIERS IN MOLECULAR BIOSCIENCES
(2021)
Article
Chemistry, Multidisciplinary
Nikoletta Naoumi, Kleita Michaelidou, George Papadakis, Agapi E. Simaiaki, Roman Fernandez, Maria Calero, Antonio Arnau, Achilleas Tsortos, Sofia Agelaki, Electra Gizeli
Summary: Regular screening of cancer point mutations is crucial for cancer management and treatment selection. A new method combining allele-specific PCR and a high fundamental frequency quartz crystal microbalance array has been developed, which can detect mutations in a fast and cost-effective manner. The method has shown high sensitivity and good agreement with results from real samples.
Article
Oncology
Maria A. Papadaki, Alexia Monastirioti, Christina A. Apostolopoulou, Despoina Aggouraki, Chara Papadaki, Kleita Michaelidou, Maria Vassilakopoulou, Katerina Alexakou, Dimitrios Mavroudis, Sofia Agelaki
Summary: This study provides evidence that the expression of TLR4 and pSTAT3 in the peripheral blood of breast cancer patients may be associated with disease progression and outcomes.
Article
Oncology
G. Mountzios, E. Samantas, K. Senghas, E. Zervas, J. Krisam, K. Samitas, F. Bozorgmehr, J. Kuon, S. Agelaki, S. Baka, I. Athanasiadis, L. Gaissmaier, M. Elshiaty, L. Daniello, A. Christopoulou, G. Pentheroudakis, E. Lianos, H. Linardou, K. Kriegsmann, P. Kosmidis, R. El Shafie, M. Kriegsmann, A. Psyrri, C. Andreadis, E. Fountzilas, C. -P. Heussel, F. J. Herth, H. Winter, C. Emmanouilides, G. Oikonomopoulos, M. Meister, T. Muley, H. Bischoff, Z. Saridaki, E. Razis, E. -I. Perdikouri, A. Stenzinger, I. Boukovinas, M. Reck, K. Syrigos, M. Thomas, P. Christopoulos
Summary: The ALI score serves as a powerful prognostic and predictive biomarker for patients with advanced NSCLC treated with PD-L1 inhibitors alone. It shows stronger association in ICI monotherapy and can help in selecting cases that do not need chemotherapy.
Article
Otorhinolaryngology
Alexander Karatzanis, Kleanthi Mylopotamitaki, Eleni Lagoudaki, Emmanuel Prokopakis, Sofia Agelaki
Summary: Clinical evaluation, differential diagnosis, and management of a neck mass are common challenges for head and neck surgeons. An asymptomatic neck mass may be the sole clinical sign of head and neck cancer. Accurate diagnosis and appropriate management are crucial in these cases.
CASE REPORTS IN OTOLARYNGOLOGY
(2022)